Avricore Health Inc.

Avricore Health Inc.

0.05
CAD
+0.00
(-9.09%)
-0.02EPS
6.95MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.07
- -
- -
- -
- -
- -
0.02
0.04
0.05
0.01
- -
Basic EPS, GAAP
0.06
-0.11
-0.19
-0.18
-0.15
-0.12
-0.04
-0.02
-0.02
-0.01
-0.01
-0.01
-0.02
-0.02
Free Cash Flow per Basic Share
-0.04
-0.09
-0.13
-0.14
-0.1
-0.05
-0.01
-0.02
-0.01
-0.02
- -
0.01
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.08
0.07
0.24
0.13
0.09
0.02
-0.01
-0.01
0.02
0.02
0.02
0.02
- -
0.01
Tangible Book Value per Share
0.05
0.02
0.24
0.13
0.05
0.01
-0.01
-0.01
0.02
0.02
0.02
0.02
- -
0.01
Basic Weighted Avg Shares
5
7
12
15
18
34
47
60
93
98
100
100
101
102
Sales/Revenue/Turnover
- -
- -
- -
1
- -
- -
- -
- -
- -
2
3
5
1
- -
Operating Margin (%)
- -
- -
-30,235.71
-230.39
- -
-16,144.9
-4,839.66
-2,583.24
-1,415.85
-45.95
-19.72
2.91
-237.21
-621.35
Depreciation Expense
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
-2
-3
-3
-4
-2
-1
-2
-1
-1
-1
-2
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-38,520.01
-257.86
- -
-27,046.76
-6,380.63
-3,554.24
-1,390.9
-46.27
-20.12
-13.98
-348.16
-933.8
Working Capital
- -
- -
3
2
1
- -
- -
-1
2
1
- -
1
- -
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
1
3
2
2
1
- -
-1
2
2
2
2
- -
1
Return on Invested Capital (%)
52.47
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-77.49
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-133.47
-109.58
-99.17
-123.94
-244.49
- -
- -
- -
-39.33
-35.3
-33.64
-157.7
-132.03

Capital Structure

CAD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
101
101
126
Market Capitalization
6
7
7

Working Capital

CAD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
- -
- -
1
Cash, Cash Equivalents & STI
- -
- -
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-67.45%
-99.65%
-80.2%
Free Cash Flow
-54.18%
-116.26%
-206.67%
Net Income, GAAP
13.36%
30.47%
177.85%
Sales/Revenue/Turnover
- -
331.46%
-88.84%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
5
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
-0.01
-0.01
2025
- -
- -
- -
-0.01
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Rodger Seccombe
Full Time Employees
26
Sector
Health technology
Industry
Pharmaceuticals: major
Address
700 – 1199 West Hastings Street Vancouver BC Canada V6E 3T5
IPO Date
Mar 27, 2001
Business
Avricore Health Inc. is a pharmacy services innovator specializing in pharmacy-based digital health solutions. The company provides a turnkey, cloud-connected point-of-care testing platform, HealthTab™, designed to support pharmacists in delivering clinical services and managing chronic diseases. Its main products include a comprehensive test menu offering up to 23 key biomarkers such as HbA1c, lipid profiles, and eGFR for screening and managing conditions like diabetes and heart disease. HealthTab™ also integrates rapid diagnostic tests for bacterial and viral infections, including strep and COVID-19. The platform combines best-in-class point-of-care devices with a secure cloud infrastructure that enables real-time data reporting, patient access, and seamless integration with third-party applications via APIs. Founded in 2013 and headquartered in Vancouver, British Columbia, Avricore primarily operates in the United Kingdom and Canada with an expanding focus on the UK healthcare market. The company’s services empower pharmacists as frontline care providers while giving patients greater control over their health through convenient, in-pharmacy testing and health data management. The HealthTab™ network model supports multiple revenue streams, including equipment leasing, consumables, disease prevention programs, decentralized clinical trials, and real-world data collection to inform health organizations and clinical research. In recent developments, Avricore has strategically shifted its focus to accelerate growth in the UK market, concluding its previous Canadian partnership with Shoppers Drug Mart and redeploying resources accordingly. In 2024 and 2025, the company expanded HealthTab™ into new NHS Integrated Care Board regions, including North Central London and North East London, as part of a groundbreaking pharmacy-led cardiovascular project and other NHS initiatives. It secured reseller agreements, such as with Abbott Rapid Diagnostics UK & Ireland, to distribute rapid testing devices. The company also integrated its platform with the UK's leading patient personal health record system, Patients Know Best, enhancing data accessibility and patient engagement. Leadership updates include the appointment of Rodger Seccombe as CEO in mid-2025. Avricore reported net profitability in early 2024 and strong revenue growth with a record year in 2024, demonstrating its progress in scaling operations and expanding clinical service offerings within community pharmacies. Overall, Avricore Health Inc. operates in the healthcare technology and pharmacy services segment, targeting pharmacies, healthcare providers, and patients with scalable digital solutions for chronic disease management and point-of-care diagnostics primarily in the UK and Canadian markets. The company emphasizes innovation in pharmacy practice and accessible health information to improve outcomes. This description is based on the latest company updates, financial reports, strategic partnerships, and product offerings through 2025.

Company News

  • HealthTab™ and HeartEye Open New Referral Pathway into Community Pharmacy

  • HealthTab™ Programme Expands Nationally Across England

  • Avricore Grants Options

  • HealthTab™ Enters Multi-Year Collaboration Agreement with Abbott for Point-of-Care Testing Across the UK

  • Avricore Health Closes $1.254 Million Financing

  • Avricore Health Announces $1.25 Million Financing

  • Avricore Health Achieves Milestones and Outlines UK Expansion Roadmap for HealthTab™ Platform

  • HealthTab™ to Expand Across North East London

  • HealthTab™ to Power NHS Pilot

  • Avricore Grants Options

  • Avricore Appoints Rodger Seccombe as CEO

  • AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Report

  • AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on track

  • HealthTab™ and Patients Know Best® Bring Pharmacy-Based Blood Test Results to Millions in UK

  • Avricore Health Corporate Update: Effective Plan, Resources Result in Success

  • Avricore Health Refocuses Strategy to Unlock Growth Potential

  • Avricore Health Recognized in Deloitte's 2024 Technology Fast 50™ Companies to Watch

  • Avricore Grants Options

  • Avricore Health Corporate Update: Mid-Year Results Show Strong Growth, Profitability

  • Avricore Health passes major milestone as it moves into profitability